Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2008 3
2009 1
2010 3
2011 3
2012 2
2013 3
2014 3
2015 5
2016 6
2017 6
2018 10
2019 7
2020 9
2021 0
Text availability
Article attribute
Article type
Publication date

Search Results

53 results
Results by year
Filters applied: . Clear all
Page 1
HLA-DR/DQ molecular mismatch: A prognostic biomarker for primary alloimmunity.
Wiebe C, Kosmoliaptsis V, Pochinco D, Gibson IW, Ho J, Birk PE, Goldberg A, Karpinski M, Shaw J, Rush DN, Nickerson PW. Wiebe C, et al. Among authors: ho j. Am J Transplant. 2019 Jun;19(6):1708-1719. doi: 10.1111/ajt.15177. Epub 2018 Dec 15. Am J Transplant. 2019. PMID: 30414349 Free PMC article.
Urinary, Plasma, and Serum Biomarkers' Utility for Predicting Acute Kidney Injury Associated With Cardiac Surgery in Adults: A Meta-analysis.
Ho J, Tangri N, Komenda P, Kaushal A, Sood M, Brar R, Gill K, Walker S, MacDonald K, Hiebert BM, Arora RC, Rigatto C. Ho J, et al. Am J Kidney Dis. 2015 Dec;66(6):993-1005. doi: 10.1053/j.ajkd.2015.06.018. Epub 2015 Aug 5. Am J Kidney Dis. 2015. PMID: 26253993 Free article. Review.
Class II Eplet Mismatch Modulates Tacrolimus Trough Levels Required to Prevent Donor-Specific Antibody Development.
Wiebe C, Rush DN, Nevins TE, Birk PE, Blydt-Hansen T, Gibson IW, Goldberg A, Ho J, Karpinski M, Pochinco D, Sharma A, Storsley L, Matas AJ, Nickerson PW. Wiebe C, et al. Among authors: ho j. J Am Soc Nephrol. 2017 Nov;28(11):3353-3362. doi: 10.1681/ASN.2017030287. Epub 2017 Jul 20. J Am Soc Nephrol. 2017. PMID: 28729289 Free PMC article.
We hypothesized that HLA class II de novo donor-specific antibody (dnDSA) development correlates with tacrolimus trough levels and the recipient's individualized alloimmune risk determined by HLA-DR/DQ epitope mismatch. ...
We hypothesized that HLA class II de novo donor-specific antibody (dnDSA) development correlates with tacrolimus trough levels and the recip …
Activity-based Protein Profiling Approaches for Transplantation.
Navarrete M, Wilkins JA, Lao Y, Rush DN, Nickerson PW, Ho J. Navarrete M, et al. Among authors: ho j. Transplantation. 2019 Sep;103(9):1790-1798. doi: 10.1097/TP.0000000000002752. Transplantation. 2019. PMID: 30985576 Review.
New developments in transplant proteomics.
Ho J, Hirt-Minkowski P, Wilkins JA. Ho J, et al. Curr Opin Nephrol Hypertens. 2017 May;26(3):229-234. doi: 10.1097/MNH.0000000000000319. Curr Opin Nephrol Hypertens. 2017. PMID: 28221173 Review.
Hyperacute Antibody-mediated Rejection Associated With Red Blood Cell Antibodies.
Shaw J, Gibson IW, Wiebe C, Houston DS, Koulack J, Rush D, Nickerson P, Ho J. Shaw J, et al. Among authors: ho j. Transplant Direct. 2019 Jul 25;5(8):e477. doi: 10.1097/TXD.0000000000000925. eCollection 2019 Aug. Transplant Direct. 2019. PMID: 31576373 Free PMC article. No abstract available.
Technical Considerations and Confounders for Urine CXCL10 Chemokine Measurement.
Handschin J, Hirt-Minkowski P, Hönger G, Mitrovic S, Savic Prince S, Ho J, Nickerson P, Schaub S. Handschin J, et al. Among authors: ho j. Transplant Direct. 2019 Dec 24;6(1):e519. doi: 10.1097/TXD.0000000000000959. eCollection 2020 Jan. Transplant Direct. 2019. PMID: 32047847 Free PMC article.
Phospholipase A2 group XV activity during cardiopulmonary bypass surgery.
Navarrete M, Wilkins JA, Chan FV, Ye B, Nickerson P, Ho J. Navarrete M, et al. Among authors: ho j. Clin Biochem. 2020 Dec 9:S0009-9120(20)30907-3. doi: 10.1016/j.clinbiochem.2020.12.003. Online ahead of print. Clin Biochem. 2020. PMID: 33307060
Urinary biomarkers of renal transplant outcome.
Ho J, Rush DN, Nickerson PW. Ho J, et al. Curr Opin Organ Transplant. 2015 Aug;20(4):476-81. doi: 10.1097/MOT.0000000000000208. Curr Opin Organ Transplant. 2015. PMID: 26107968 Review.
A noninferiority design for a delayed calcineurin inhibitor substitution trial in kidney transplantation.
Nickerson PW, Balshaw R, Wiebe C, Ho J, Gibson IW, Bridges ND, Rush DN, Heeger PS. Nickerson PW, et al. Among authors: ho j. Am J Transplant. 2020 Sep 21. doi: 10.1111/ajt.16311. Online ahead of print. Am J Transplant. 2020. PMID: 32956576
Our analysis indicates an evidence-based noninferiority margin of 13.8% for the United States Food and Drug Administration's composite definition of BPAR between 6 and 24 months posttransplant. ...
Our analysis indicates an evidence-based noninferiority margin of 13.8% for the United States Food and Drug Administration's composit …
53 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page
Feedback